FeesSafety
Pluang+
Asset icon - trade crypto, stocks, and gold on Pluang

Royal Caribbean Cruises Ltd (RCL) Stock Price Today

24H
1W
1M
3M
YTD
1Y
5Y

DeGen Medical moves to dismiss Carlsmed's patent suit over spinal implant methods.

DeGen Medical has filed a motion to dismiss key parts of a patent infringement lawsuit from Carlsmed, which claims DeGen's patient-specific spinal implants infringe on eight patents. DeGen argues that the contested patents cover abstract, computer-im...

Market News
5 hours ago
Na
Neutral
DeGen Medical moves to dismiss Carlsmed's patent suit over spinal implant methods.

American Savings Bank seen as hold due to strong profits but high valuation and Hawaii risks.

American Savings Bank (ASBH), recently public, is rated a hold by Crimson And Gold Research. The bank benefits from low deposit costs and solid profitability, with a 0.68% deposit cost supporting a 3.61% net interest margin. However, its valuation is...

Market News
6 hours ago
Seeking Alpha
Neutral
American Savings Bank seen as hold due to strong profits but high valuation and Hawaii risks.

CarMax and Carvana compete as used-car buying shifts online amid rising new car prices.

CarMax, a leading used-car retailer, faces growing competition from online challenger Carvana as more buyers shift to digital car purchases. Carvana's CEO claims they are close to becoming the largest used-car retailer in the U.S., while CarMax's CEO...

Market News
7 hours ago
PYMNTS
Neutral
CarMax and Carvana compete as used-car buying shifts online amid rising new car prices.

Microsoft's use of Cerebras chips signals rising AI competition against Nvidia's dominance.

Microsoft's adoption of Cerebras chips marks a significant development in the AI hardware space, indicating growing competition to Nvidia's leading position. While this move is positive for Cerebras, the analyst remains cautious and continues to hold...

Market News
7 hours ago
Seeking Alpha
Neutral
Microsoft's use of Cerebras chips signals rising AI competition against Nvidia's dominance.

China includes Ascentage Pharma's lisaftoclax and renews olverembatinib coverage in 2026 National Reimbursement Drug List

Ascentage Pharma announced that its cancer drugs lisaftoclax and olverembatinib are now covered by China's 2026 National Reimbursement Drug List (NRDL), effective January 1, 2027. Lisaftoclax is newly included for treating chronic lymphocytic leukemi...

Market News
10 hours ago
GlobeNewsWire
Bullish
news icon
China includes Ascentage Pharma's lisaftoclax and renews olverembatinib coverage in 2026 National Reimbursement Drug List

All patients in Alpha Tau's glioblastoma trial alive with 100% tumor response and no serious side effects

Alpha Tau Medical announced interim results from its U.S. trial of Alpha DaRT therapy for recurrent glioblastoma, showing all eight treated patients are alive with a median follow-up of 6.9 months and no median survival reached. Among six patients as...

Market News
10 hours ago
Na
Bullish
news icon
All patients in Alpha Tau's glioblastoma trial alive with 100% tumor response and no serious side effects

Tesla and SpaceX lose $420B in market value after Democrats win midterms amid probe fears

Tesla and SpaceX saw a combined market value drop of over $420 billion within two days following the Democratic Party's sweep in the midterm elections. Investors are concerned that the new Democratic-controlled Congress may initiate investigations in...

10 hours ago
The Motley Fool
Bearish
news icon
Tesla and SpaceX lose $420B in market value after Democrats win midterms amid probe fears

IDEAYA nominates IDE101, a novel dual CDK inhibitor targeting CDKN2A-deficient tumors, aiming for FDA filing in H1 2027.

IDEAYA Biosciences announced IDE101 as a new development candidate designed to treat tumors with CDKN2A deficiency, common in 10-15% of solid tumors including 70% of pancreatic cancers. IDE101 is a first-in-class dual cyclin-dependent kinase inhibito...

Market News
13 hours ago
PRNewsWire
Bullish
news icon
IDEAYA nominates IDE101, a novel dual CDK inhibitor targeting CDKN2A-deficient tumors, aiming for FDA filing in H1 2027.

Nvidia earnings, Anthropic IPO, and GTA 6 launch mark a pivotal week for AI and gaming sectors.

Nvidia reports earnings with new CFO Colette Kress amid concerns over Jensen Huang's departure and Singapore revenue scrutiny. Expectations are $2.47 EPS and $108.73 billion revenue, with mixed analyst views on AI adoption risks and stock potential. ...

14 hours ago
Seeking Alpha
Bullish
news icon
Nvidia earnings, Anthropic IPO, and GTA 6 launch mark a pivotal week for AI and gaming sectors.

Widows filing Social Security benefits in the wrong order lose up to $56,000 over a lifetime.

A 63-year-old widow with a $900,000 IRA lost about $56,000 by claiming her larger Social Security survivor benefit first instead of her smaller retirement benefit. The Social Security Administration's audit found many widows could gain an average of ...

Market News
15 hours ago
247 Wallst
Neutral
Widows filing Social Security benefits in the wrong order lose up to $56,000 over a lifetime.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

Key Stats

  • Market Cap
    $86.47B
  • Volume
    1,244,661
  • Sector
    Consumer Cyclical
  • 52W High
    $348.03
  • 52W Low
    $230.30
  • Typical Hold Time
    87 Days
  • Enterprise Value
    $108.78B
  • Div Yield
    1.86%
  • Trading Activity
    -
$322.6
52W Low: $230.3
23 Sep 2026
52W High: $348.03
09 Feb 2026

Track Royal Caribbean Cruises Ltd (RCL) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Royal Caribbean Cruises Ltd has traded between a low of $230.3 and a high of $348.03, highlighting its annual price range. Buy and sell Royal Caribbean Cruises Ltd shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!